[Form 4] VolitionRX Limited Insider Trading Activity

Rhea-AI Filing Summary

VolitionRX Limited insider filing (Form 4) reports that director and officer Nicholas Plummer was awarded 24,031 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The RSUs are granted under the Issuer's 2015 Stock Incentive Plan, have a reported price of $0, and will be earned in six approximately equal monthly installments beginning 09/01/2025. Once earned, the awards remain subject to additional time-based vesting in two installments of 12,016 units on 11/01/2025 and 12,015 units on 02/01/2026. The filing shows 207,877 shares beneficially owned by the reporting person following the transaction.

Positive

• 24,031 RSUs granted to replace cash compensation, as explicitly stated in the filing
• Clear vesting schedule: earned in six monthly installments beginning 09/01/2025, with further time-based vesting on 11/01/2025 and 02/01/2026
• Beneficial ownership after transaction is reported as 207,877 shares

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider awarded 24,031 RSUs in lieu of cash; vesting spans Sept 2025–Feb 2026; beneficial ownership rises to 207,877 shares.

The filing documents a compensation-related equity grant rather than an open-market purchase or sale. The award replaces cash compensation and is structured with an initial earning phase across six monthly installments followed by two time-based vesting dates, which delays full share delivery until late 2025/early 2026. This transaction is a routine executive compensation action and does not itself convey operational performance metrics.

Corporate Governance Expert

TL;DR: Company used its 2015 Stock Incentive Plan to issue RSUs as compensation; vesting provisions require continued service.

The Form 4 discloses standard RSU terms: awards earned monthly then subject to further time-based vesting, and settlement converts RSUs into common shares upon vesting. The filing identifies the reporting person as a director and officer (GC - Volition Diagnostics). The structure ties compensation to service periods documented in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plummer Nicholas

(Last) (First) (Middle)

1489 WEST WARM SPRINGS ROAD

SUITE 110

(Street)

HENDERSON NV 89014

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GC - Volition Diagnostics

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		A		24,031(1)	A	$0	207,877	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On August 15, 2025, the reporting person was awarded 24,031 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in six approximately equal monthly installments commencing on September 1, 2025. Once earned, they will remain subject to additional time-based vesting in two installments of 12,016 units and 12,015 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date.

Remarks:

	/s/ Nicholas Plummer	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many RSUs were granted to Nicholas Plummer on 08/15/2025 (VNRX)?

The filing states 24,031 restricted stock units (RSUs) were awarded on 08/15/2025.

What is the vesting schedule for the RSUs reported on the Form 4?

RSUs are earned in six approximately equal monthly installments beginning 09/01/2025, then subject to additional time-based vesting in two installments of 12,016 units on 11/01/2025 and 12,015 units on 02/01/2026.

Was cash paid for these RSUs according to the filing?

No; the RSUs were granted in lieu of cash compensation, and the reported price for the transaction is $0.

How many shares does the reporting person beneficially own after the transaction?

The Form 4 reports 207,877 shares beneficially owned following the reported transaction.

What role does the reporting person hold at VolitionRX?

The filing identifies Nicholas Plummer as a Director and an Officer with title noted as GC - Volition Diagnostics.